Advertisement
Advertisement
Related Posts
Mark Sorial, PharmD, BCOP, shared the latest research from the Salvia Jain Lab's PETAL Consortium.
Bexobrutideg, an orally bioavailable, brain-penetrant BTK degrader, is being evaluated in a phase 1a/b study.
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Machine learning may aid point-of-care clinical decision-making for NHL patients receiving CAR T-cell therapy.
Some major themes for practice include identifying patients at risk for early progression and emphasis on quality of life.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.